Subtopic Deep Dive

Proteasome Inhibitors in Cancer Therapy
Research Guide

What is Proteasome Inhibitors in Cancer Therapy?

Proteasome inhibitors are drugs that block 20S/26S proteasome activity to induce apoptosis in cancer cells reliant on high protein turnover, with bortezomib as the first FDA-approved agent for multiple myeloma.

Bortezomib (PS-341) inhibits proteasome function, suppressing growth and inducing apoptosis in multiple myeloma cells (Hideshima et al., 2001, 1529 citations). Phase 2 trials demonstrated its efficacy in relapsed, refractory myeloma (Richardson et al., 2003, 2619 citations). These inhibitors trigger a terminal unfolded protein response selective for myeloma cells (Obeng et al., 2006, 1133 citations).

Curated Papers

Key Challenges

Why It Matters

Proteasome inhibitors like bortezomib provide a targeted therapy for hematologic malignancies such as multiple myeloma, where high protein synthesis creates dependency on proteasome activity (Hideshima et al., 2001). Clinical success in relapsed patients established proteasome blockade as a viable strategy, overcoming conventional chemotherapy resistance (Richardson et al., 2003). Ongoing developments extend to PROTACs for broader protein degradation in solid tumors (Békés et al., 2022). This approach influences combination regimens in clinical trials for both hematologic and solid cancers.

Key Research Challenges

Drug Resistance Development

Cancer cells adapt to bortezomib via upregulated alternative degradation pathways or mutations (Obeng et al., 2006). Combination therapies are explored but require identifying synergistic targets (Hideshima et al., 2001). Clinical translation faces variability in patient responses (Richardson et al., 2003).

Selectivity for Tumor Cells

Proteasome inhibition affects normal cells, causing toxicity; myeloma selectivity arises from terminal unfolded protein response (Obeng et al., 2006). Achieving tumor-specific degradation remains challenging (Békés et al., 2022). PROTACs aim to improve this but face delivery issues.

Expanding to Solid Tumors

Efficacy proven in hematologic cancers but limited in solid tumors due to lower proteasome dependency (Richardson et al., 2003). New inhibitors targeting specific subunits are needed (Hideshima et al., 2001). Clinical trials show mixed results requiring better biomarkers.

Essential Papers

PROTAC targeted protein degraders: the past is prologue

Miklós Békés, David R. Langley, Craig M. Crews · 2022 · Nature Reviews Drug Discovery · 2.7K citations

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · 2003 · New England Journal of Medicine · 2.6K citations

Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.

The <scp>BioGRID</scp> database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions

Rose Oughtred, Jennifer Rust, Christie Chang et al. · 2020 · Protein Science · 1.8K citations

Abstract The BioGRID (Biological General Repository for Interaction Datasets, thebiogrid.org ) is an open‐access database resource that houses manually curated protein and genetic interactions from...

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Teru Hideshima, Paul G. Richardson, D Chauhan et al. · 2001 · PubMed · 1.5K citations

Human multiple myeloma (MM) is a presently incurable hematological malignancy, and novel biologically based therapies are urgently needed. Proteasome inhibitors represent a novel potential anticanc...

The Biology of Proteostasis in Aging and Disease

Johnathan Labbadia, Richard I. Morimoto · 2015 · Annual Review of Biochemistry · 1.4K citations

Loss of protein homeostasis (proteostasis) is a common feature of aging and disease that is characterized by the appearance of nonnative protein aggregates in various tissues. Protein aggregation i...

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)

Fatima Ardito, Michele Giuliani, D. Perrone et al. · 2017 · International Journal of Molecular Medicine · 1.3K citations

Protein phosphorylation is an impo-rtant cellular regulatory mechanism as many enzymes and receptors are activated/deactivated by phosphorylation and dephosphorylation events, by means of kinases a...

Histone Deacetylase Inhibitors as Anticancer Drugs

Tomáš Eckschlager, Johana Plch, Marie Stiborová et al. · 2017 · International Journal of Molecular Sciences · 1.1K citations

Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene exp...

Reading Guide

Foundational Papers

Start with Hideshima et al. (2001) for mechanism in myeloma cells; Richardson et al. (2003) for phase 2 trial efficacy; Obeng et al. (2006) for unfolded protein response selectivity.

Recent Advances

Békés et al. (2022) on PROTACs as next-generation degraders; Đikić (2017) comparing proteasome and autophagy systems.

Core Methods

Bortezomib binds β5 subunit; PROTACs recruit E3 ligases for ubiquitination; assays measure chymotrypsin-like activity and UPR markers (Hideshima et al., 2001; Békés et al., 2022).

How PapersFlow Helps You Research Proteasome Inhibitors in Cancer Therapy

Discover & Search

Research Agent uses searchPapers and citationGraph to map bortezomib literature from Hideshima et al. (2001), revealing 1529 citing papers on resistance mechanisms. exaSearch finds combination therapy trials; findSimilarPapers expands to PROTACs like Békés et al. (2022).

Analyze & Verify

Analysis Agent applies readPaperContent to extract apoptosis pathways from Obeng et al. (2006), then verifyResponse with CoVe checks claims against Richardson et al. (2003) trial data. runPythonAnalysis performs GRADE grading on survival stats and plots dose-response curves from abstracts using pandas/matplotlib.

Synthesize & Write

Synthesis Agent detects gaps in solid tumor applications via contradiction flagging across Hideshima (2001) and Békés (2022). Writing Agent uses latexEditText, latexSyncCitations for trial summaries, and latexCompile to generate a review manuscript with exportMermaid for proteasome pathway diagrams.

Use Cases

"Analyze bortezomib dose-response data from multiple myeloma trials for IC50 trends."

Research Agent → searchPapers('bortezomib IC50 myeloma') → Analysis Agent → readPaperContent(Richardson 2003) + runPythonAnalysis(pandas aggregation of survival/IC50 from 5 papers) → matplotlib plot of trends.

"Write a LaTeX section on proteasome inhibitor mechanisms with citations."

Synthesis Agent → gap detection(Hideshima 2001 + Obeng 2006) → Writing Agent → latexEditText('mechanism text') → latexSyncCitations(10 papers) → latexCompile → PDF with unfolded protein response figure.

"Find code for simulating proteasome inhibition models from related papers."

Research Agent → citationGraph(Békés 2022) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for PROTAC degradation kinetics.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ bortezomib papers: searchPapers → citationGraph → DeepScan(7-step verification with CoVe checkpoints) → structured report on resistance. Theorizer generates hypotheses on PROTAC combinations from Hideshima (2001) and Békés (2022). DeepScan analyzes Obeng (2006) UPR data with runPythonAnalysis for statistical validation.

Try Doxa for Proteasome Inhibitors in Cancer Therapy Research

Frequently Asked Questions

What defines proteasome inhibitors in cancer therapy?

Drugs like bortezomib reversibly bind the 20S proteasome's chymotrypsin-like site, blocking protein degradation and triggering apoptosis in high-turnover cancers such as multiple myeloma (Hideshima et al., 2001).

What are key methods of proteasome inhibitors?

Bortezomib inhibits the 26S proteasome, inducing terminal unfolded protein response; PROTACs leverage ubiquitin ligases for targeted degradation (Békés et al., 2022; Obeng et al., 2006).

What are foundational papers?

Hideshima et al. (2001, 1529 citations) showed PS-341 induces apoptosis in myeloma; Richardson et al. (2003, 2619 citations) confirmed clinical activity in relapsed patients; Obeng et al. (2006, 1133 citations) detailed UPR mechanism.

What open problems exist?

Overcoming resistance in solid tumors, improving selectivity via subunit-specific or PROTAC inhibitors, and optimizing combinations for broader efficacy (Richardson et al., 2003; Békés et al., 2022).